Profile data is unavailable for this security.
About the company
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
- Revenue in USD (TTM)3.17bn
- Net income in USD-486.37m
- Incorporated2019
- Employees6.13k
- LocationBiontech SEAn der Goldgrube 12MAINZ 55131GermanyDEU
- Phone+49 49 613190840
- Fax+49 61 319084390
- Websitehttps://www.biontech.com/
Mergers & acquisitions
| Acquired company | 22UA:GER since announced | Transaction value |
|---|---|---|
| Biotheus Inc | 6.89% | 800.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Summit Therapeutics Inc | 0.00 | -196.68m | 14.01bn | 105.00 | -- | 31.98 | -- | -- | -0.2768 | -0.2768 | 0.00 | 0.5941 | 0.00 | -- | -- | 0.00 | -54.53 | -77.32 | -71.71 | -86.35 | -- | -- | -- | -20,989.46 | -- | -- | 0.053 | -- | -100.00 | -- | -680.54 | -- | -4.84 | -- |
| Moderna Inc | 5.08bn | -2.22bn | 15.82bn | 5.60k | -- | 1.33 | -- | 3.11 | -5.81 | -5.81 | 13.14 | 30.98 | 0.2883 | 2.44 | 2.96 | 907,321.40 | -12.62 | 20.95 | -15.52 | 29.51 | 78.43 | -- | -43.77 | 32.10 | 4.20 | -- | 0.0521 | 0.00 | -64.45 | 119.28 | -156.37 | -- | 46.22 | -- |
| United Therapeutics Corporation | 2.76bn | 1.11bn | 16.65bn | 1.17k | 16.39 | 2.73 | 14.14 | 6.04 | 22.75 | 22.75 | 56.36 | 136.74 | 0.3897 | 2.43 | 9.18 | 2,359,760.00 | 15.71 | 10.38 | 17.73 | 11.27 | 88.94 | 91.47 | 40.31 | 29.25 | 4.41 | -- | 0.0615 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
| ICON PLC | 8.31bn | 747.89m | 17.69bn | 42.25k | 23.82 | 1.81 | 13.72 | 2.13 | 8.99 | 8.99 | 99.87 | 118.39 | 0.4852 | -- | 2.99 | 202,112.50 | 4.37 | 3.93 | 5.24 | 4.80 | 29.65 | 28.91 | 9.00 | 7.37 | -- | 4.41 | 0.2599 | -- | 4.89 | 25.62 | 21.18 | 13.67 | 23.79 | -- |
| BioNTech SE - ADR | 3.17bn | -486.37m | 27.12bn | 6.13k | -- | 1.36 | -- | 8.56 | -2.04 | -2.04 | 13.12 | 83.05 | 0.1363 | 1.04 | 2.03 | 516,365.50 | -2.09 | 37.91 | -2.32 | 44.76 | 87.71 | 83.82 | -15.36 | 50.36 | 7.21 | -- | 0.0126 | 4.73 | -77.94 | 97.35 | -90.14 | -- | 60.06 | -- |
| Iqvia Holdings Inc | 15.32bn | 1.41bn | 36.65bn | 88.00k | 26.48 | 5.26 | 14.44 | 2.39 | 7.62 | 7.62 | 83.09 | 38.36 | 0.5762 | -- | 4.77 | 176,034.50 | 5.31 | 3.24 | 7.13 | 4.07 | 35.17 | 34.32 | 9.21 | 6.03 | -- | 3.43 | 0.6598 | 0.00 | 3.98 | 7.55 | 24.47 | 43.39 | 7.17 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Baillie Gifford & Co.as of 30 Sep 2024 | 8.31m | 3.50% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 4.86m | 2.05% |
| PRIMECAP Management Co.as of 30 Sep 2024 | 4.52m | 1.90% |
| Flossbach von Storch SEas of 30 Sep 2024 | 4.36m | 1.83% |
| Temasek Holdings Pte Ltd. (Investment Management)as of 30 Sep 2024 | 1.81m | 0.76% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 1.54m | 0.65% |
| FIAM LLCas of 30 Sep 2024 | 1.12m | 0.47% |
| Capital Research & Management Co. (International Investors)as of 30 Sep 2024 | 1.02m | 0.43% |
| Capital International, Inc.as of 30 Sep 2024 | 930.47k | 0.39% |
| Candriam Belgium SAas of 30 Sep 2024 | 927.16k | 0.39% |
